Skip to main content

Table 7 Summary of non-controlled studies and outcomes

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Effects of omalizumab in patients with urticaria: uncontrolled studies

Author (year)

Urticary type

N

No response

Partial response

Complete response

Ivyanskiy (2012)

CIU 12, AIU 6, DPU 1

19

3

5

11

Ferrer (2011)

CSU

9

2

5

2

Groffik (2011)

CSU

9

0

4

5

Sánchez-Machín (2011)

CSU

1

0

0

1

Saavedra (2011)

CSU

1

0

0

1

Krause (2010)

Dermographic U

1

0

0

1

Buller Kotte (2010)

Heat U

1

0

0

1

Binslej-Jensen(2010)

DPU

1

0

0

1

Magerl (2010)

CSU

8

0

1

7

Al-Ahmad (2010)

AIU

3

0

0

3

Kemoli (2010)

AIU

1

0

0

1

Sabroe (2010)

Cholinergic U

1

1

0

0

Waiber (2009)

Solar U

1

0

1

0

Maspero (2009)

AIU

1

0

0

1

Kaplan (2008)

AIU

12

1

4

7

Güzelbey (2008)

Solar U

1

0

0

1

Metz (2008)

Cholinergic U

1

0

0

1

Godse (2008)

CSU

3

0

0

3

Sands (2007)

CAU

3

0

0

3

Spector (2007)

2 AIU, 1 CSU

3

0

0

3

TOTAL

 

78

7(8,9%)

20 (25,6%)

51 (65,3%)

  1. CIU: Chronic Idiopathic Urticaria; AIU: Aspirin induced Urticaria; DPU: Delayed Pressure Urticaria; CSU: Chronic Spontaneous Urticaria; CAU: Chronic Autoinmune Urticaria.